In this Q&A, Richard Frank, MD, MHSA, Chief Medical Officer at Vida, breaks down what the data actually shows: Oral and injectable semaglutides deliver similar weight loss, safety, and side-effect profiles, with both averaging around 15% weight reduction over more than a year
However, for frequent travelers or anyone without reliable refrigeration, this could be something to seriously consider when determining what works best for your lifestyle
Vendors offering dramatically cheaper products typically cut corners somewhere
Moreover, as the market for weight loss medications continues to grow, companies should invest in clinical research to expand the approved indications for their drugs, ensuring that they can meet the demand for effective and safe obesity treatments without violating FDA regulations